<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03792386</url>
  </required_header>
  <id_info>
    <org_study_id>R/17.06.52</org_study_id>
    <nct_id>NCT03792386</nct_id>
  </id_info>
  <brief_title>Combined Ultrasound and Fluoroscopy Guided Cervical Transforaminal Injection</brief_title>
  <official_title>Clinical Visibility of Combined Ultrasound and Fluoroscopy Guided Cervical Transforaminal Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The combined use of Doppler ultrasound and fluoroscopy may increase efficacy and safety&#xD;
      during cervical transforaminal epidural injection of steroid and local anaesthetic&#xD;
&#xD;
      The study will detect by which technique we have to start and confirm by the other to reach&#xD;
      the favourable outcome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a previous Ultrasound study involving the C5C6 levels, a performance time of 248.8 Â± 82.7&#xD;
      seconds was reported. On the basis of these findings, a 30% difference in performance time&#xD;
      would represent an effect size of 0.82 and would require 20 patients per group to achieve an&#xD;
      alpha error of 0.05 and beta error of 0.1. For dropped cases; 5% will be added. So a total&#xD;
      sample size of 64 patients (32 per group) will be required.&#xD;
&#xD;
      Statistical Analysis: will be performed using SPSS version 22 statistical software. For&#xD;
      quantitative data, normality will be first assessed with the Shapiro test and then analyzed&#xD;
      with the Student t-test. Data that will not have a normal distribution, as well as ordinal&#xD;
      data, will be analyzed with the Mann-Whitney U test. For binomial data, Fisher exact test&#xD;
      will be used. All P values presented will be 2-sided and values of less than 0.05 will be&#xD;
      considered significant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 15, 2019</start_date>
  <completion_date type="Actual">July 15, 2019</completion_date>
  <primary_completion_date type="Actual">June 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>performance time in minutes</measure>
    <time_frame>starting by direction of the spinal needle towards the nerve root till confirmation of correct placement of the needle and injection over a period of 15 minutes</time_frame>
    <description>Defined as time needed for correct transforaminal needle placement through ultrasound guidance followed by fluoroscopic confirmation or fluoroscopic guidance followed by ultrasound confirmation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility of the radiologic target</measure>
    <time_frame>starting by direction of the spinal needle towards the nerve root till confirmation of correct placement of the needle and injection over a period of 15 minutes</time_frame>
    <description>number of needle corrections till confirmation of correct placement of the needle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analogue score</measure>
    <time_frame>pre-procedure then every 3 months till 6 months after the procedure</time_frame>
    <description>Visual analogue score (VAS, 11-point scale): using 100mm visual analogue score in which 0 mm represents no pain and 100mm worst pain imaginable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neck disability index</measure>
    <time_frame>pre-procedure then every 3 months till 6 months after the procedure</time_frame>
    <description>Neck disability index (NDI, 35-point scale); 0-4points (0-8%) no disability, 5-14points (10 - 28%) mild disability, 15-24points (30-48% ) moderate disability, 25-34points (50- 64%) severe disability, 35-50points (70-100%) complete disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of patient satisfaction</measure>
    <time_frame>pre-procedure then every 3 months till 6 months after the procedure</time_frame>
    <description>Level of patient satisfaction (5-point scale); Very dissatisfied Dissatisfied Neutral Satisfied Very satisfied</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Chronic Cervical Radicular Pain</condition>
  <arm_group>
    <arm_group_label>Ultrasound guidance with fluoroscopic confirmation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in which the intervention will be performed using ultrasound guidance with fluoroscopic confirmation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluoroscopic guidance with ultrasonographic confirmation.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in which intervention will be performed using fluoroscopic guidance with ultrasonographic confirmation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrasound guidance with fluoroscopic confirmation</intervention_name>
    <description>the cervical spine will be sonographically examined to determine the C7 transverse process then after lidocaine skin infiltration, a 22G spinal needle is directed towards the hypoechoic shadow of the nerve root using the in-plane technique. then 1ml of non-ionic contrast will be injected and AP and the oblique foraminal fluoroscopic view will be obtained. After confirmation of correct placement of the needle,(2ml, 8mg dexamethasone plus 1ml Lidocaine 1%) will be injected.</description>
    <arm_group_label>Ultrasound guidance with fluoroscopic confirmation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fluoroscopic guidance with ultrasonographic confirmation.</intervention_name>
    <description>After AP view, alignment or squaring of the target lower end plate, an oblique foraminal view is obtained. Following lidocaine 1% skin infiltration, a 22G spinal needle is directed towards the target foramen then, the superficial ultrasound probe will be applied to delineate the foramen. The needle will be advanced ~3mm towards the dorsal root ganglia under fluoroscopic guidance. After contrast confirmation of needle placement, 2ml,8mg dexamethasone plus 1ml Lidocaine 1%) will be injected.</description>
    <arm_group_label>Fluoroscopic guidance with ultrasonographic confirmation.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients suffering from radicular discogenic pain&#xD;
&#xD;
          -  Patients suffering from radicular foraminal pain Patients suffering from radicular&#xD;
             pain secondary to spinal canal stenosis&#xD;
&#xD;
          -  Patients suffering from radicular pain after failed cervical disc surgery&#xD;
&#xD;
          -  Not responding to conservative management for at least 3 months&#xD;
&#xD;
          -  Patients with recalcitrant symptoms after transforaminal steroid injection.&#xD;
&#xD;
          -  American Society of Anesthesiology (ASA) from I to III&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of local or systemic infection&#xD;
&#xD;
          -  Coagulopathy&#xD;
&#xD;
          -  Body mass index &gt; 35&#xD;
&#xD;
          -  Cervical spine fracture&#xD;
&#xD;
          -  Myelopathy&#xD;
&#xD;
          -  Malignancy&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients unable to communicate with the operator during the procedure or report their&#xD;
             pain diary after it.&#xD;
&#xD;
          -  Patients not responding to previous cervical transforaminal steroid injection or had&#xD;
             any untoward effects.&#xD;
&#xD;
          -  Allergy to any one of the used medications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enas A Abd el Motlb, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Associate Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Enas A Abd el Motlb</name>
      <address>
        <city>Mansourah</city>
        <state>DK</state>
        <zip>050</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 1, 2019</study_first_submitted>
  <study_first_submitted_qc>January 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2019</study_first_posted>
  <last_update_submitted>September 6, 2020</last_update_submitted>
  <last_update_submitted_qc>September 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

